Zobrazeno 1 - 10
of 152
pro vyhledávání: '"Douglas E, Gladstone"'
Autor:
Edina Komlodi-Pasztor, Marta Escarra-Senmarti, Danielle A. Bazer, Aastha Bhatnagar, Carlos A. Perez Heydrich, Marcus Messmer, Richard F. Ambinder, Douglas E. Gladstone, Laura Clayton, Amy Goodrich, Laura Schoch, Nina Wagner-Johnston, Christopher J. VandenBussche, Peng Huang, Matthias Holdhoff, Maximillian Rosario
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The monoclonal antibody rituximab improves clinical outcome in the treatment of CD20-positive lymphomatous neoplasms, and it is an established drug for treatment of these cancers. Successful mRNA COVID-19 (SARS-CoV-2) vaccination is extremely importa
Externí odkaz:
https://doaj.org/article/231eb2a41b7d476ea9cd7853570c0c4f
Autor:
Farhad Ravandi, Robert J. Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C. Barrientos, Seema A. Bhat, James S. Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sasha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E. Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B. Johnston, Jeffrey Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A. Parikh, Jae H. Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A. Rogers, Alan Saven, John F. Seymour, Tamar Tadmor, Martin S. Tallman, Constantine S. Tam, Philip A. Thompson, Xavier Troussard, Clive S. Zent, Thorsten Zenz, Pier Luigi Zinzani, Bernhard Wörmann, Kanti Rai, Michael Grever
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 12, Pp 1-7 (2022)
Abstract A significant body of literature has been generated related to the detection of measurable residual disease (MRD) at the time of achieving complete remission (CR) in patients with hairy cell leukemia (HCL). However, due to the indolent natur
Externí odkaz:
https://doaj.org/article/b522c851a9074f98bd78424982d9e633
Autor:
Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Tadeusz Robak, Philipp D. le Coutre, Bjørn T. Gjertsen, Xavier Troussard, Gail J. Roboz, Lionel Karlin, Douglas E. Gladstone, Nataliya Kuptsova-Clarkson, Shiyao Liu, Priti Patel, Federico Rotolo, Emmanuel Mitry, Ira Pastan, Francis Giles, the Study 1053 investigators
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-11 (2021)
Abstract Background Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here, we present the long-term follow-up analysis of the pivotal, multicenter, open-label trial (NCT01829711) of moxetumomab pasudotox in patients with relapsed/re
Externí odkaz:
https://doaj.org/article/036b0eca00dd402a9a89af31dbc023b1
Autor:
John N. Allan, Javier Pinilla-Ibarz, Douglas E. Gladstone, Krish Patel, Jeff P. Sharman, William G. Wierda, Michael Y. Choi, Susan M. O’Brien, Mazyar Shadman, Matthew S. Davids, John M. Pagel, Habte A. Yimer, Renee Ward, Gary Acton, Pietro Taverna, Daniel L. Combs, Judith A. Fox, Richard R. Furman, Jennifer R. Brown
Publikováno v:
Haematologica, Vol 107, Iss 4 (2021)
Externí odkaz:
https://doaj.org/article/2b83f0254400461d8896d202887eadb7
Autor:
Philip H. Imus, Hua-Ling Tsai, Leo Luznik, Ephraim J. Fuchs, Carol Ann Huff, Douglas E. Gladstone, Patrick Lowery, Richard F. Ambinder, Ivan M. Borrello, Lode J. Swinnen, Nina Wagner-Johnston, Christian B. Gocke, Syed Abbas Ali, F.Javier Bolaños-Meade, Ravi Varadhan, Richard J. Jones
Publikováno v:
Blood Advances, Vol 3, Iss 17, Pp 2608-2616 (2019)
Abstract: Hematologic malignancies in older people are unlikely to be cured with chemotherapy alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially nonmyeloablative (NMA) conditioning and the use of haploidentical donors
Externí odkaz:
https://doaj.org/article/197de5e065234acea249f8b75efa3cfa
Autor:
Paolo Strati, Michelle A. Fanale, Yasuhiro Oki, Francesco Turturro, Luis E Fayad, Nancy L. Bartlett, Douglas E. Gladstone, Yvette L. Kasamon, Carol S. Portlock, Wyndham H. Wilson, Andre Goy, Anas Younes, Hun Ju Lee
Publikováno v:
Haematologica, Vol 104, Iss 2 (2019)
Externí odkaz:
https://doaj.org/article/470e13ff9e8941a0b332712295d8a3f5
Autor:
Jonathan Allen Webster, Madison C. Reed, Hua-Ling Tsai, Alexander J. Ambinder, Tania Jain, Amy E. DeZern, Mark J. Levis, Margaret M. Showel, Gabrielle T. Prince, Christopher S. Hourigan, Javier Bolaños-Meade, Lukasz P. Gondek, Gabriel Ghiaur, William Brian Dalton, Suman Paul, Ephraim J. Fuchs, Christian B. Gocke, Abbas Abbas Ali, Douglas E. Gladstone, Carol Ann Huff, Ivan M. Borrello, Lode J. Swinnen, Nina D. Wagner-Johnston, Richard F. Ambinder, Leo Luznik, Ivana Gojo, B. Douglas Douglas Smith, Ravi Varadhan, Richard J. Jones, Philip H. Imus
Publikováno v:
Blood. 140:4813-4815
Autor:
Yvette L. Kasamon, Richard F. Ambinder, Ephraim J. Fuchs, Marianna Zahurak, Gary L. Rosner, Javier Bolaños-Meade, Mark J. Levis, Douglas E. Gladstone, Carol Ann Huff, Lode J. Swinnen, William H. Matsui, Ivan Borrello, Robert A. Brodsky, Richard J. Jones, Leo Luznik
Publikováno v:
Blood Advances, Vol 1, Iss 4, Pp 288-292 (2017)
Abstract: Allogeneic blood or marrow transplantation (BMT) candidates may lack HLA-matched, related haploidentical, and unrelated umbilical cord options. Barriers to partially HLA-mismatched, unrelated donor (mMUD) BMT include excess graft-versus-hos
Externí odkaz:
https://doaj.org/article/af2ec2c8d00b48949c2586a19a5e7f02
Autor:
Amy E. DeZern, Alexander J. Ambinder, Matthew D. Smith, Carol Ann Huff, Christian B. Gocke, Douglas E. Gladstone, Gabriel Ghiaur, William Dalton, Philip H. Imus, Mark J. Levis, Lukasz P. Gondek, Jonathan Webster, Ivana Gojo, Gabrielle T. Prince, Tania Jain, Margaret M. Showel, Ivan Borrello, Ravi Varadhan, Javier Bolaños-Meade, Hua-Ling Tsai, B. Douglas Smith, Nina Wagner-Johnston, Leo Luznik, Syed Abbas Ali, Richard Jones, Richard F. Ambinder, Ephraim J. Fuchs, Lode J. Swinnen
Publikováno v:
Clin Lymphoma Myeloma Leuk
Introduction Mutations in the IDH1 or IDH2 genes are detected in approximately 20% of cases of acute myeloid leukemia (AML). Few studies have examined the impact of IDH mutations in AML on allogeneic bone marrow transplant (alloBMT) outcomes. Patient
Autor:
Brandy, Perkins, Margaret, Showel, Laura, Schoch, Philip H, Imus, Theodoros, Karantanos, Raluca, Yonescu, Laura, Morsberger, Gabriel, Ghiaur, Douglas E, Gladstone, Richard J, Jones
Publikováno v:
Leuk Lymphoma
The clinical course of chronic lymphocytic leukemia (CLL) is highly variable. Immunoglobulin heavy chain variable region (IgHV) mutation status is among the most important prognostic factors, with unmutated IgHV associated with inferior outcomes. CLL